Claritev Corp (CTEV) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Claritev Corporation (formerly MultiPlan Corporation) is a leading provider of data-driven cost management solutions for the healthcare industry. The company changed its name and ticker symbol to "CTEV" in February 2025. All share and per-share data presented have been retroactively adjusted for a 1-for-40 reverse stock split effective September 20, 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues | $241,570 | $233,476 | $472,900 | $467,984 |
| Operating Income (Loss) | $16,578 | $(523,927) | $26,320 | $(1,010,363) |
| Net Loss | $(62,640) | $(576,727) | $(133,959) | $(1,116,416) |
| Adjusted EBITDA | $154,028 | $146,670 | $296,097 | $293,460 |
| Cash & Equivalents | $56,390 | $48,767 | $56,390 | $48,767 |
| Total Debt (Gross) | $4,588,074 | $4,565,737 | $4,588,074 | $4,565,737 |
| Net Cash Provided by Operating Activities (YTD) | $31,181 | $68,187 | $31,181 | $68,187 |
Note: Q2 2024 results were significantly impacted by a $553.7 million goodwill impairment charge, which did not occur in Q2 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.5% in Q2 2025 and 1.1% YTD compared to the prior year. This was driven by an 18.4% increase in Network-Based Services and a 9.4% increase in Payment and Revenue Integrity Services, partially offset by a 1.8% decline in Analytics-Based Services due to customer attrition in percentage-of-savings contracts.
- Profitability Improvement: The company returned to operating profitability ($16.6M) in Q2 2025, a stark contrast to the $523.9M operating loss in Q2 2024. The prior year's loss was primarily due to a non-cash goodwill impairment charge of $553.7 million.
- Expense Increases: General and Administrative (G&A) expenses rose 53.2% in Q2 2025, driven by $7.9 million in transformation costs and $1.8 million in asset disposal losses. Interest expense increased 22.9% due to the recognition of $26.0 million in PIK (Payment-in-Kind) interest on new debt instruments.
- Refinancing Transaction: In January 2025, the company completed a major refinancing, exchanging existing notes for new "First-Out," "Second-Out," and "Third-Out" lien notes and term loans. This resulted in $7.9 million of transaction costs expensed in the first half of 2025.
Guidance, Outlook, and Risks
- Outlook: Management does not provide specific numerical guidance in this filing but highlights a strategic shift toward international expansion, specifically a partnership in the Middle East and North Africa (MENA) region. The company expects to identify approximately $12.5 billion in potential medical cost savings for the six months ended June 30, 2025.
- Liquidity: As of June 30, 2025, the company held $67.3 million in cash and restricted cash. It has $263.6 million of availability under its new $350 million revolving credit facility. The company believes current sources are sufficient for the next 12 months.
- Risks and Contingencies:
- Antitrust Litigation: The company is a defendant in consolidated federal class action lawsuits alleging antitrust violations regarding out-of-network reimbursement suppression. Discovery is ongoing, and the company intends to vigorously defend these claims.
- Debt Covenants: The company is subject to a financial covenant requiring a consolidated first-out, first-lien debt-to-EBITDA ratio not to exceed 2.50 to 1.00 if revolver utilization exceeds 40%. As of June 30, 2025, the company was in compliance.
- Customer Concentration: Two clients accounted for 28% and 16% of revenues in 2024, respectively.
Investor Verification Checklist
- Debt Structure Complexity: Verify the specific terms, interest rates (cash vs. PIK), and maturity dates of the new "First-Out," "Second-Out," and "Third-Out" debt tranches issued in the January 2025 refinancing.
- Goodwill Valuation: Confirm the stability of the $2.4 billion goodwill balance and the assumptions used in the latest impairment testing, given the significant impairments recorded in 2024.
- Antitrust Exposure: Monitor the status of the consolidated antitrust litigation in the Northern District of Illinois and any potential settlement accruals.
- Revenue Mix Shift: Analyze the trend of declining "Percentage of Savings" (PSAV) revenue versus growing "Per Employee Per Month" (PEPM) revenue to assess the stability of future cash flows.
- Transformation Costs: Track the run-rate of "transformation costs" ($15.7M YTD 2025) to determine if these are one-time or recurring operational expenses.